Abdominal Cutaneous Nerve Entrapment Syndrome

Abdominal Pain Clinical Trial

— ACNES  

Official title:

The Management of Abdominal Cutaneous Nerve Entrapment Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03574727
• Other study ID #: 2017AN003
• Status: Completed
• Start date: September 15, 2017
• Est. completion date: September 19, 2018

Study information

• Verified date: September 2019
• Source: University of Aberdeen
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Nerve entrapment as a cause of chronic abdominal pain is frequently overlooked. A series of nerves pass through the muscles of the abdomen before reaching the skin to carry sensations. They can get trapped within the muscles leading to severe pain resulting in a condition known as Abdominal Cutaneous Nerve Entrapment Syndrome (ACNES). ACNES affects between 10-30% of patients with chronic abdominal wall pain. A definitive diagnosis of ACNES is obtained by anaesthetising these nerves. Initial management includes education and avoidance of known triggers. It is common practice to inject steroid with local anaesthetic during the diagnostic injections itself to prolong pain relief. Like other nerve entrapment conditions, this is also refractory to medical treatment. Hence repeated injections and nerve entrapment release surgery are commonly carried out.

In Aberdeen, a number of patients have been treated for this condition. A cohort of patients have benefitted with injection alone while recurrence has been noted in patients who have undergone surgery. This project aims to gain more understanding about the clinical course of patients with suspected ACNES by evaluation of the clinic progress.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: September 19, 2018
• Est. primary completion date: September 19, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

In order to be eligible for inclusion, all patients must:

• Be aged 16 or over

• Be able to understand English

• Be able to give informed consent

• Be able to report on their health and pain status (neurologically stable)

• Should have undergone either injection or surgery for suspected ACNES

Exclusion Criteria:

Patients will be excluded if they:

• Are not able to understand what is required of them

• Are not able to give informed consent

Related Conditions & MeSH terms

• Abdominal Cutaneous Nerve Entrapment Syndrome
• Abdominal Pain
• Charcot-Marie-Tooth Disease
• Hereditary Sensory and Motor Neuropathy
• Nerve Compression Syndromes
• Syndrome

Intervention

Procedure:
• Injection to or release of anterior cutaneous nerves
Patients who have undergone at least one injection to the nerves

Locations

Country	Name	City	State
United Kingdom	Aberdeen Royal Infirmary	Aberdeen	Scotland

Sponsors (2)

Lead Sponsor	Collaborator
University of Aberdeen	NHS Grampian

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Success rate of intervention	An intervention either injection or surgery is classed as success when there is either a 2 point difference in the average pain scores pre and post intervention or more than 30% improvement as rated by the participant in the Brief Pain Inventory used for evaluating the pain baseline and follow-up.	3 months